The Attributable Burden of Hypertension: Focus on CKD

Advances in Chronic Kidney Disease

Volumn 18, Issue 1, 2011, Pages 6-10

  Jamerson, Kenneth A ^a,b   Townsend, Raymond R ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hypertension; Renal disease

Indexed keywords

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEATH; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERBARISM; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY INJURY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; UREMIA; WORLD HEALTH ORGANIZATION;

COMORBIDITY; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 78651076425     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.11.006     Document Type: Review

References (42)

1. Lewis J.B. Blood pressure control in chronic kidney disease: is less really more?. J Am Soc Nephrol 2010, 21:1086-1092.
2. Muntner P., Anderson A., Charleston J., et al. Hypertension awareness, treatment, and control in adults with chronic kidney disease: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2009, 55:441-451.
3. MacMahon S., Alderman M.H., Lindholm L.H., Liu L., Sanchez R.A., Seedat Y.K. Blood-pressure-related disease is a global health priority. Am J Hypertens 2008, 21:843-844.
4. Eknoyan G., Lameire N., Barsoum R., et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004, 66:1310-1314.
5. Heron M., Hoyert D.L., Murphy S.L., Xu J., Kochanek K.D., Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009, 57:1-134.
6. Omran A.R. The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q 1971, 49:509-538.
7. Chobanian A.V. Shattuck lecture. The hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med 2009, 361:878-887.
8. Mascie-Taylor C.G., Karim E. The burden of chronic disease. Science 2003, 302:1921-1922.
9. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
10. Lawes C.M., Vander H.S., Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008, 371:1513-1518.
11. 2009 WHO Global Health report. Available at: Accessed October 4, 2010. http://www.who.int/healthinfo/global_burden_disease/en/index.html.
12. Lopez A.D., Mathers C.D., Ezzati M., Jamieson D.T., Murray C.J.L. Global Burden of Disease and Risk Factors 2006, University Press, New York, NY.
13. Walker R.W., McLarty D.G., Kitange H.M., et al. Stroke mortality in urban and rural Tanzania. Adult Morbidity and Mortality Project. Lancet 2000, 355:1684-1687.
14. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. Clin Nephrol 1996, 334:13-18.
15. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997, 277:1293-1298.
16. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
17. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
18. Perera G.A. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955, 1:33-42.
19. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967, 202:1028-1034.
20. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970, 213:1143-1152.
21. Castelli W.P. Epidemiology of coronary heart disease: the Framingham Study. Am J Med 1984, 76(suppl 2A):4-12.
22. Haider A.W., Larson M.G., Franklin S.S., Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003, 138:10-16.
23. Kannel W.B., Wolf P.A., McGee D.L., Dawber T.R., McNamara P., Castelli W.P. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981, 245:1225-1229.
24. Feldman H.I., Appel L.J., Chertow G.M., et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. J Am Soc Nephrol 2003, 14:S148-S153.
25. Furth S.L., Cole S.R., Moxey-Mims M., et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 2006, 1:1006-1015.
26. Lash J.P., Go A.S., Appel L.J., et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009, 4:1302-1311.
27. Imai E., Matsuo S., Makino H., et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 2008, 31:1101-1107.
28. Shishehbor M.H., Oliveira L.P., Lauer M.S., et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008, 101:1741-1746.
29. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
30. Kao W.H., Klag M.J., Meoni L.A., et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185-1192.
31. Freedman B.I., Kopp J.B., Langefeld C.D., et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010, 21:1422-1426.
32. Barker D.J. Birth weight and hypertension. Hypertension 2006, 48:357-358.
33. Barker D.J. The origins of the developmental origins theory. J Intern Med 2007, 261:412-417.
34. Hill G.S., Heudes D., Jacquot C., Gauthier E., Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006, 69:823-831.
35. Loutzenhiser R., Griffin K., Williamson G., Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1153-R1167.
36. O'Rourke M.F., Safar M.E. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005, 46:200-204.
37. Klahr S. The kidney in hypertension-villain and victim. N Engl J Med 1989, 320:731-733.
38. Wheatley K., Ives N., Gray R., et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009, 361:1953-1962.
39. Bax L., Woittiez A.J., Kouwenberg H.J., et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009, 150:840-841.
40. Scarpioni R., Michieletti E., Cristinelli L., et al. Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER). J Nephrol 2005, 18:423-428.
41. Schieppati A., Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int 2003, 64:1947-1955.
42. Appel L.J., Wright J.T., Greene T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363:918-929.